APG-2575（Lisaftoclax）是亚盛医药自主研发的、具全球best-in-class潜力的新型口服Bcl-2选择性抑制剂，在多种血液肿瘤和实体瘤治疗领域具备广阔的治疗潜力。亚盛医药将在此次ASH年会上，口头报告该品种治疗复发/难治（R/R）多发性骨髓瘤 ...

The discovery of the Bcl-2 protein family, as well as p53 and its involvement in regulating apoptosis, and the CD95 (also known as FAS or APO1) pathway, led to an understanding of the molecular ...

p53 lies at the hub of a vast signalling network. Polymorphisms in upstream activators, repressors or downstream effectors of p53 might individually modulate cancer risk or interact with ...

摘要： 癌细胞对化疗药物的耐药性大大降低了癌症患者的治疗效果，化疗引起的毒副作用也严重影响了患者的生活质量。茶中主要活性成分表没食子儿茶素-3-没食子酸酯（EGCG）与顺铂、5-FU、多柔比星和紫杉醇的联合使用，增强了它们对肿瘤的增敏效果，并对抗了癌细胞的耐药性。这些效应似乎通过多种机制介导，包括对抗癌症干细胞介导的药物耐药性、增强药物敏感性、诱导细胞周期停滞和凋亡，以及阻断血管生成。此外，EGC ...

Under normal, unstressed conditions, a key negative regulator of p53 is MDM2, which binds to the ... SOCS2 = suppressor of cytokine signalling 2; SOD2 = superoxide dismutase; [Mn] = mitochondrial ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...

The five-drug combination decreased the levels of BCL-2, BCL-xL and MCL-1, suggesting its potential clinical relevance in overcoming ABT199/venetoclax resistance. Moreover, this combination is active ...

Abgent是您的一个抗体服务中心。 Abgent的细胞凋亡抗体产品主要集中在Bci-2蛋白的BH3结构域。除此之外，还包括针对ABL,BRAF,p53,和TAO等新的靶点的抗体。 Abgent已开发了关于染色质调控、转录调控和翻译调控方面的2700多个抗体产品，用于细胞核水平调控的检测。

There is evidence that lower doses may be equally effective, especially in patients with less severe edema. [10] If beneficial, neurological improvement can be expected within 48 h with this ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

He clarified his position in a Facebook post last night, saying many students, including those from the movement, had been compelled to join BCL in the past. For all latest news, follow The Daily ...